Targets › CLDN18A2
1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout Mar 2027.
Open in Phaseline: the race on CLDN18A2, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Beijing Biotech | EBNK-1822H2 Dual-target CLDN18.2/HER2 CAR-NK cells | CLDN18A2, ERBB2 | Phase 1 | Recurrent or Metastatic Esophageal Adenocarcinoma | Mar 2027 |
Recurrent or Metastatic Esophageal Adenocarcinoma (1)
mixed (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.